Search results for " mAbs" in Articles / App Notes

Article How to Address Bioburden Challenges: Insights and Tips
Bioburden control is an area of serious concern for anyone making mAbs or other biologicals. Manufacturers’ efforts to avoid microbial contamination are today being complemented by developments from…

Article Fusion Proteins Pose Manufacturability Challenges
The unique structures of fusion proteins lead to expression, heterogeneity, and stability issues. By Cynthia A. Challener Fusion proteins are engineered proteins that contain domains from di…

Article Mechanistic Modeling of Preparative Ion-Exchange Chromatography
By Anurag Rathore, Vijesh Kumar Among the various downstream processing unit operations that are used for purification of biotech products, chromatography is uniquely capable of providing resolu…

Article Applications of Surface Plasmon Resonance for Detection of Bispecific Antibody Activity
Surface plasmon resonance is helping define bispecific antibodies, the next-generation of biopharma therapeutics. By Robert Karlsson Abstract Biotherapeutic antibodies are still the larg…

Article SEC in the Modern Downstream Purification Process
Mar 01, 2015 By R. Christopher Manzari, J. Kevin O'Donnell BioPharm International Volume 3, Issue 28 Since the introduction of commercial chromatography resins approximately six de…

Article The Bullish Outlook for Biosimilars
Feb 01, 2015 By Jill E. Sackman, PhD, Michael J. Kuchenreuther, PhD BioPharm International There are several important reasons for stakeholders to be optimistic about prospects for b…

Article Milestones and Moderate Progress in 2012 Drug Approvals
First gene therapy and plant-based expression vector products approved in 2012. In terms of product approvals, the past year can be considered reasonably successful. Twelve biopharm…

Article Address the complexity of protein characterization
Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant clinical success and have been used to provide effective treatment for a range of diseases. Durin…

Article Downstream Process Developers: What are Your Antibody Processing Challenges?
Process developers, we want to hear from you! We're asking PD scientists to tell us about their biggest challenges developing downstream processes for mAbs and their variants.  Take this …

Article Webinar: Intensifying downstream bioprocessing with continuous technologies
Webinar on June 20, 2024 Significant operational improvements can be achieved by intensified continuous processes compared to standard batch processes. In this webinar we will explor…

Show All Results

Previous PageNext Page